Modulation of cellular insulin signaling and PTP1B effects by lipid metabolites in skeletal muscle cells

Journal of Nutritional Biochemistry

Volumn 24, Issue 8, 2013, Pages 1529-1537

  Obanda, Diana N ^a   Cefalu, William T ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

AKt; Ceramides; Diglycerides; Insulin signaling; PTP1B; Triglycerides

Indexed keywords

CERAMIDE; DIACYLGLYCEROL; FATTY ACID; INSULIN; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; TRIACYLGLYCEROL; WORTMANNIN;

ARTICLE; GLYCOGEN ANALYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MUSCLE CELL; MYOBLAST; MYOTUBE; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

AKT; C14:0; C16:0; C16:1; C18:0; C18:1; C18:2; C2 TO C24; CERAMIDE C2 TO CERAMIDE C24; CERAMIDES; DAGS; DIGLYCERIDES; FFAS; FREE FATTY ACIDS; INSULIN SIGNALING; LINOLEIC ACID; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; PTP1B; SER; SERINE; STEARIC ACID; TAGS; TRIGLYCERIDES; TYR; TYROSINE;

ANIMALS; CELLS, CULTURED; CERAMIDES; DIGLYCERIDES; FATTY ACIDS, NONESTERIFIED; GLYCOGEN; INSULIN RESISTANCE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOBLASTS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SERINE; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

RATTUS;

EID: 84892436297     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.12.014     Document Type: Article

References (45)

1. Koves T.R., Ussher J.R., Noland R.C., Slentz D., Mosedale M., Ilkayeva O., et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008, 7:45-56.
2. Kraegen E.W., Cooney G.J., Gregory J. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008, 9(3):235-241.
3. Hirabara S.M., Curi R., Maechler P. Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol 2010, 222:187-194.
4. Kraegen E.W., Cooney G.J., Ye J., Thompson A.L. Triglycerides, fatty acids and insulin resistance-hyperinsulinemia. Exp Clin Endocrinol Diabetes 2001, 109(4):516-526.
5. Chavez J.A., Summers S.A. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. 2003a. Arch Biochem Biophys 2003, 419:101-109.
6. Chavez J.A., Knotts T.A., Wang L.P., Li G., Dobrowsky R.T., Florant G.L., et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003, 13:10297-10303.
7. Obanda D.N., Hernandez A., Ribnicky D., Yu Y., Zhang X.H., Wand Z.Q., et al. Bioactives of Artemisia dracunculus L. mitigate the role of ceramides in attenuating insulin signaling in rat skeletal muscle cells. Diabetes 2012, 61.
8. Dimopoulos N., Watson M., Sakamoto K., Hundal H.S. Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. Biochem J 2006, 399:473-481.
9. Krebs M., Roden M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab 2005, 7:621-632.
10. Sabin M.A., Stewart C.E., Crowne E.C., Turner S.J., Hunt L.P., Welsh G.I., et al. Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intramyocellular lipid. J Cell Physiol 2007, 211:244-252.
11. Morino K., Petersen K.F., Shulman G.I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006, 55(Suppl 2):S9-S15.
12. Montell E., Turini M., Marotta M., Roberts M., Noe V., Ciudad C.J., et al. DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am J Physiol 2001, 280:E229-E237.
13. Powell D.J., Turban S., Gray A., Hajduch E., Hundal H.S. Intracellular ceramide synthesis and protein kinase C zeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J 2004, 382:619-629.
14. Gomez-Lechon M.J., Ponsoda X., Cadtell J.V. A microassay for measuring glycogen in 96-well cultured cells. Anal Biochem 1996, 236:296-301.
15. Wang Z.Q., Ribnicky D., Zhang X.H., Raskin I., Yu Y., Cefalu W.T. Bioactives of Artemisia dracunculus L enhance cellular insulin signaling in primary human skeletal muscle culture. Metab Clin Exp 2008, 57(Suppl 1):S58-S64.
16. Smith A.C., Mullen K.L., Junkin K.A., et al. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet induced hyperglycemia. Am J Physiol Endocrinol Metab 2007, 293:E172-E181.
17. Mathew M., Tay E., Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 2010, 9:9.
18. Frayn K.N., Williams C.M., Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases?. Clin Sci (Lond) 1996, 90:243-253.
19. An J., Muoio D.M., Shiota M., Fujimoto Y., Cline G.W., Shulman G.I., et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole animal insulin resistance. Nat Med 2004, 10:268-274.
20. Monetti M., Levin M.C., Watt M.J., Sajan M.P., Marmor S., Hubbard B.K., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007, 6:69-78.
21. Liu L., Zhang Y., Chen N., et al. Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest 2007, 117:1679-1689.
22. Goodpaster B.H., He J., Watkins S., Kelley D.E. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001, 86:5755-5761.
23. Bruce C.R., Kriketos A.D., Cooney G.J., Hawley J.A. Disassociation of muscle triglyceride content and insulin sensitivity after exercise training in patients with type 2 diabetes. Diabetologia 2004, 47:23-30.
24. Jazet I.M., Schaart G., Gastaldelli A., et al. Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signaling in obese insulin-treated type 2 diabetic patients. Diabetologia 2008, 51:309-319.
25. Lara-Castro C., Newcomer B.R., Rowell L., et al. Effects of short term very low calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metab Clin Exp 2008, 57:1-8.
26. Bajaj M., Madina-Navarro R., Suraamornkul S., et al. Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration. Diabetes 2007, 56:743-752.
27. Lê K.A., Faeh D., Stettler R., et al. A 4-wk high fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr 2006, 84:1374-1379.
28. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006, 45(1):42-72.
29. Wadley G.D., Konstantopoulos N., Macaulay L., Howlett K.F., Garnham A., Hargreaves M., et al. Increased insulin-stimulated AKt pSer473 and cytosolic SHP2 protein abundance in human skeletal muscle following acute exercise and short-term training. J Appl Physiol 2007, 102(4):1624-1631.
30. Gingras A.A., White P.J., Chouinard P.Y., Julien P., Davis T.A., Dombrowski L., et al. Long-chain omega-3 fatty acids regulate bovine whole-body protein metabolism by promoting muscle insulin signalling to the AKt-mTOR-S6K1 pathway and insulin sensitivity. J Physiol 2007, 579:269-284.
31. Lee J.S., Pinnamaneni S.K., Eo S.J., Cho I.H., Pyo J.H., Kim C.K., et al. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 2006, 100:1467-1474.
32. Storlien L.H., Hulbert A.J., Else P.L. Polyunsaturated fatty acids, membrane function and metabolic diseases such as diabetes and obesity. Curr Opin Clin Nutr Metab Care 1998, 1:559-560.
33. Zhang Zhong-Yin, Lee Seung-Yub PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003, 12(2):223-233.
34. Goldstein B.J., Bittner-Kowalczyk A., White M.F., et al. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein phosphatase 1B. Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein. J Biol Chem 2000, 275:4283.
35. Goldstein B. Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance. Curr Drug Targets Immune Endocr Metabol Disord 2001, 1(3):265-275.
36. Taghvaei N.M., Meshkani R., Taghikhani M., Larijani B., Adeli K. Palmitate enhances protein tyrosine phosphatase 1B (PTP1B) gene expression at transcriptional level in C2C12 skeletal muscle cells. Inflammation 2011, 34:1.
37. Calera M.R., Vallega G., Pilch P.F. Dynamics of protein-tyrosine phosphatases in rat adipocytes. J Biol Chem 2000, 275:6308.
38. Seely B.L., Staubs P.A., Reichart D.R., et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 1996, 45:1379.
39. Jiang G., Zhang B.B., Moller D.E. New therapies to promote insulin action. Diabetes mellitus: a fundamental and clinical text 2004, 1226-1234. Lippincott Williams & Wilkins, Philadelphia, PA. Ed 3. D. LeRoith, S.I. Taylor, J.M. Olefsky (Eds.).
40. Bakhtiyari S., Meshkani R., Taghikhani M., Larijani B., Adeli K. Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Lipids 2010, 45(3):237-244.
41. Johnson T.O., Ermolieff J., Jirousek M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov 2002, 1:696-709.
42. Bhanot S, Monia BP, Geary RS, Kjems LL. Antisense modulation of PTP1B expression. US Patent No. US2009/0036355 A1. 2009.
43. Bandyopadhyay D., Kusari A., Kenner K.A., et al. Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J Biol Chem 1997, 272:1639.
44. Dadke S., Kusari A., Kusari J. Phosphorylation and activation of protein tyrosine phosphatase (PTP) 1B by insulin receptor. Mol Cell Biochem 2001, 221:147.
45. Ravichanran L.V., Chen H., LI Y., Quon M.J. Phosphorylation of PTP1B at Ser(50) by AKt impairs its ability to dephosphorylate the insulin receptor. Mol Endocrinol 2001, 15(10):1768-1780.